🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. HBS-101, White, round, plain, biconvex film-coated tablet. Matching 4.45 mg tablet is 3.7 mm in diameter., White, round, plain, biconvex film-coated tablet. matching 17.8 mg tablet is 7.5 mm in diameter., WAKIX, HBS-101, WAKIX

    Harmony Biosciences Holdings

    Prader-Willi syndrome

    phase 3 small molecule active

    1 trial

  2. HEPARIN , NADROPARIN

    Disc Medicine

    All patients who receive ECMO treatment during the study period in one the participating centers from which (deferred) informed consent is obtained. Patients in whom the ECMO is only used to bridge a procedure like a high risk percutaneous coronary intervention or during surgery are excluded.

    phase 3 small molecule active

    1 trial

  3. HETLIOZ 20 mg hard capsules, Placebo will be provided in size and appearance identical to those containing tasimelteon and will be administered orally.

    Lacuna Pharma Pty Ltd

    Delayed Sleep-Wake Phase Disorder (DSWPD)

    phase 3 small molecule active

    1 trial

  4. HIPEC with neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  5. HLD200 methylphenidate hydrochloride capsules

    COLLEGIUM PHARMACEUTICAL, INC

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  6. HOLOXAN 2000 mg, poudre pour usage parentéral, DETICENE 100 mg, poudre et solvant pour solution pour perfusion, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Resectable, non-metastatic soft-tissue sarcoma (STS)

    phase 3 small molecule active

    1 trial

  7. HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo for empasiprubart- solution for IV infusion, Placebo for IVIg - solution for IV infusion, ARGX-117

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  8. HYCAMTIN 4 mg powder for concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  9. HYDROCORTISONE, PREDNISONE ACETATE, ENZALUTAMIDE, DEXAMETHASONE ACETATE, PREDNISONE, Opevesostat, ABIRATERONE ACETATE, DEXAMETHASONE, HYDROCORTISONE , HYDROCORTISONE, FLUDROCORTISONE, ABIRATERONE ACETATE, PREDNISOLONE, HYDROCORTISONE, FLUDROCORTISONE ACETATE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  10. HYQVIA

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy

    phase 3 mab completed

    2 trials

  11. HealthWise South Africa curriculum

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 3 other completed

    1 trial

  12. Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection

    Hoffmann-La Roche

    Mild or moderate hemophilia A without FVIII inhibitors

    phase 3 small molecule active

    1 trial

  13. Herceptin 150 mg powder for concentrate for solution for infusion, DS-8201a, Perjeta 420 mg concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    Early stage HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

  14. Herceptin 150 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Solid Malignant Tumors

    phase 3 small molecule active

    1 trial

  15. Herzuma 150 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DS-8201a, CAPECITABINE, 5-Fluorouracil Ebewe 50 mg/ml concentrat pentru soluţie injectabilă/perfuzabilă, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CAPECITABINE, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi Sankyo

    Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer

    phase 3 small molecule active

    1 trial

  16. Herzuma 420 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, Perjeta 420 mg concentrate for solution for infusion, CYCLOPHOSPHAMIDE, DS-8201a, PACLITAXEL, DOXORUBICIN, Herzuma 150 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE

    AstraZeneca AB

    Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)

    phase 3 small molecule active

    1 trial

  17. Houyanqing Oral Liquid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Cancinoma (NPC)

    phase 3 small molecule active

    1 trial

  18. Human Insulin Inhalation Powder

    Eli Lilly and Company

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  19. Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Norovirus Infections

    phase 3 mab completed

    1 trial

  20. Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)

    Takeda

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  21. Humira 20 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Humira 80 mg solution for injection in pre-filled syringe, Humira 40 mg/0.8 ml solution for injection

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  22. Humira 40 mg solution for injection in pre-filled syringe, Risankizumab, Humira 20 mg solution for injection in pre-filled syringe, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Juvenile Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  23. HyQvia 100 mg/ml solution for infusion for subcutaneous use, HyQvia 100 mg/ml solution for infusion for subcutaneous use, TAK-881

    Takeda

    Primary Immunodeficiency Diseases

    phase 3 small molecule active

    1 trial

  24. Hypnotic Medication Open-Label Taper

    BRIGHT MINDS BIOSCIENCES INC.

    Hypnotic Dependence Among Those With Insomnia

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources